Even when individual tumors show reactivity, the high inter-lesional heterogeneity in expression suggests that HER2-directed therapies should primarily be considered in metastatic prostate cancer cases in which HER2 expression has been confirmed across more than one site (38). Here, ERBB2 is linked to metastatic prostate carcinoma.